Premium
A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate‐to‐severe atopic eczema
Author(s) -
Weidinger S.,
Apfelbacher C.
Publication year - 2019
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.17329
Subject(s) - dupilumab , excellence , guideline , medicine , atopic dermatitis , critical appraisal , family medicine , medline , dermatology , alternative medicine , pathology , political science , law